

LISI POSTS A NEW IMPROVEMENT IN RESULTS IN 2012 THANKS TO AEROSPACE

More progress at the strategic level

- Sales revenues €1.08 billion (up 16.9%), including organic growth of 8.8%
- EBIT €100.4m sharply up: +29%
- Improvement in current operating margin: 9.3%, close to the nominal target of 10%
- Free Cash Flow still positive: €38m after €78m in investments
- Continued reduction in borrowings: - €26m to €77m
- Average return on capital employed up by 2.2 points: 15.5% before tax

Accentuated contrasts in performance between divisions

- LISI AEROSPACE achieved 91% of the consolidated EBIT
- LISI AUTOMOTIVE felt the full impact of the slowdown of the two French car manufacturers
- LISI MEDICAL continued its repositioning

Dividend: €1.40 per share

Ongoing dynamic outlook in aerospace, but more uncertain in automotive and in the recovery in medical

Belfort, February 20, 2012 – The LISI Board of Directors has met under the chairmanship of Mr. Gilles Kohler and reviewed the finalized financial statements for the period ended December 31, 2012. They will be submitted for approval to the General Meeting on April 25, 2013.

<i>12 months ending December 31,</i>		<i>2012</i>	<i>2011*</i>	<i>Change</i>
Key elements of the income statement				
Sales revenue	€m	1,081.3	925.1	+ 16.9%
EBITDA	€m	154.8	122.1	+ 26.8%
EBITDA margin	%	14.3	13.2	+ 1.1 pts
EBIT	€m	100.4	78.1	+ 28.6%
Current operating margin	%	9.3	8.4	+ 0.9 pts
Earnings attributable to holders of company equity	€m	57.3	59.2	- 3.2%
Net earnings per share	€	5.47	5.70	- 4.0%
Key elements of the cash flow statements				
Operating cash flow	€m	119.7	95.3	+ 25.6%
Net CAPEX	€m	- 78.4	- 64.9	+ 20.8%
Free Cash Flow	€m	38.5	6.4	
Key elements of the financial structure				
Net debt	€m	76.7	102.6	-25.2%
Ratio of net debt to equity		13.3%	19.1%	- 5.8 pts

* Since the Group had made early adoption of the revised version of IAS 19 on 01.01.12, the 2011 financial statements have been restated.

OUTLOOK: Ongoing dynamic outlook in aerospace, but more uncertain in automotive and in the recovery in medical

The Group benefits from a very solid financial situation, which will allow it to grasp opportunities that might occur in the aerospace or medical fields and to continue its ambitious industrial investments plan in its three divisions. LISI is in this way demonstrating the validity of its long-term strategy model that is based on areas with quite different business cycles. Continued growth will remain balanced between internal and external growth, together with constant management efforts.

Contact

Emmanuel Viellard

Telephone: +33 (0)3 84 57 00 77

Email: emmanuel.viellard@lisi-group.com

Website: www.lisi-group.com

The next announcements will appear after close of trading on Euronext Paris

Q1 2013 financial information: April 25, 2013

Shareholders' General Meeting: April 25, 2013

H1 2013 results: July 24, 2013

Q3 2013 financial Information: October 24, 2013

LISI shares are listed on the Eurolist compartment B market and are part of the CAC MID 100 – Next 150 index under the ISIN code: FR 0000050353. LISI is a worldwide leading manufacturer of fasteners and assembly components for the Aerospace, Automotive, and medical implants industries. LISI MEDICAL specializes in the subcontracting of implants for groups developing medical solutions.

Reuters:GFII.PA
Bloomberg:FII FP

